Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance

The epidermal growth factor receptor (EGFR) secondary kinase domain T790M non–small cell lung cancer (NSCLC) mutation enhances receptor catalytic activity and confers resistance to the reversible tyrosine kinase inhibitors gefitinib and erlotinib. Currently, irreversible inhibitors represent the pri...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Shimamura, Takeshi, Li, Danan, Ji, Hongbin, Haringsma, Henry J., Liniker, Elizabeth, Borgman, Christa L., Lowell, April M., Minami, Yuko, McNamara, Kate, Perera, Samanthi A., Zaghlul, Sara, Thomas, Roman K., Greulich, Heidi, Kobayashi, Susumu, Chirieac, Lucian R., Padera, Robert F., Kubo, Shigeto, Takahashi, Masaya, Tenen, Daniel G., Meyerson, Matthew, Wong, Kwok-Kin, Shapiro, Geoffrey I.
Format: Artigo
Idioma:Inglês
Publicat: 2008
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3272303/
https://ncbi.nlm.nih.gov/pubmed/18632637
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-07-5428
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars